These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 33528040)
41. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Conde-Agudelo A; Romero R Am J Obstet Gynecol; 2009 Jun; 200(6):595-609. PubMed ID: 19482113 [TBL] [Abstract][Full Text] [Related]
42. Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. McPherson JA; Rouse DJ; Grobman WA; Palatnik A; Stamilio DM Obstet Gynecol; 2014 Oct; 124(4):749-755. PubMed ID: 25198275 [TBL] [Abstract][Full Text] [Related]
43. [Prevention of cerebral palsy using magnesium sulfate in pre-term newborns]. Marret S; Chollat C; Levèque C; Marpeau L Arch Pediatr; 2011 Mar; 18(3):324-30. PubMed ID: 21257296 [TBL] [Abstract][Full Text] [Related]
44. Outcome at 2 years of children 23-27 weeks' gestation born in Victoria in 1991-92. The Victorian Infant Collaborative Study Group. J Paediatr Child Health; 1997 Apr; 33(2):161-5. PubMed ID: 9145362 [TBL] [Abstract][Full Text] [Related]
45. Authors' reply re: Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: Time range for treatment with magnesium sulphate. Wolf HT; Brok J; Henriksen TB; Hegaard HK; Greisen G; Weber T; Pryds O; Salvig JD; Hedegaard M; Pinborg A; Huusom LD BJOG; 2020 Sep; 127(10):1296-1297. PubMed ID: 32427415 [No Abstract] [Full Text] [Related]
46. [Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth]. Wolf HT; Henriksen TB; Larsen ML; Pinborg A; Hegaard HK; Brok JS; Huusom LD Ugeskr Laeger; 2020 Nov; 182(47):. PubMed ID: 33215580 [TBL] [Abstract][Full Text] [Related]
47. Cerebral Palsy in Very Preterm Infants: A Nine-Year Prospective Study in a French Population-Based Tertiary Center. Chollat C; Bertrand E; Petit-Ledo A; de Vansay C; Voisin C; Dabaj I; Gillibert A; Marret S; J Pediatr; 2021 Oct; 237():183-189.e6. PubMed ID: 34144033 [TBL] [Abstract][Full Text] [Related]
48. Prenatal Tobacco Exposure and Childhood Neurodevelopment among Infants Born Prematurely. Robbins LS; Blanchard CT; Sinkey RG; Harris SL; Tita AT; Harper LM Am J Perinatol; 2021 Feb; 38(3):218-223. PubMed ID: 32862421 [TBL] [Abstract][Full Text] [Related]
49. Magnesium sulfate for the prevention of cerebral palsy. Rouse DJ Am J Obstet Gynecol; 2009 Jun; 200(6):610-2. PubMed ID: 19482114 [TBL] [Abstract][Full Text] [Related]
50. Prenatal Magnesium Sulfate and Functional Connectivity in Offspring at Term-Equivalent Age. Ufkes S; Kennedy E; Poppe T; Miller SP; Thompson B; Guo J; Harding JE; Crowther CA JAMA Netw Open; 2024 May; 7(5):e2413508. PubMed ID: 38805222 [TBL] [Abstract][Full Text] [Related]
52. Proximity of magnesium exposure to delivery and neonatal outcomes. Turitz AL; Too GT; Gyamfi-Bannerman C Am J Obstet Gynecol; 2016 Oct; 215(4):508.e1-6. PubMed ID: 27177525 [TBL] [Abstract][Full Text] [Related]
53. Antenatal exposure to magnesium sulfate and neuroprotection in preterm infants. Costantine MM; Drever N Obstet Gynecol Clin North Am; 2011 Jun; 38(2):351-66, xi. PubMed ID: 21575805 [TBL] [Abstract][Full Text] [Related]
54. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: The magnum study. Poppe T; Thompson B; Boardman JP; Bastin ME; Alsweiler J; Deib G; Harding JE; Crowther CA; EBioMedicine; 2020 Sep; 59():102957. PubMed ID: 32858399 [TBL] [Abstract][Full Text] [Related]
55. Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. Teela KC; De Silva DA; Chapman K; Synnes AR; Sawchuck D; Basso M; Liston RM; von Dadelszen P; Magee LA; BMC Pregnancy Childbirth; 2015 Dec; 15():347. PubMed ID: 26694323 [TBL] [Abstract][Full Text] [Related]
56. A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth. Hellström S; Jonsdotter A; Jonsson M; Pettersson K; Saltvedt S; Herbst A; Ågren J; Ådén U; Domellöf M; Hagberg H; Carlsson Y Acta Obstet Gynecol Scand; 2023 Dec; 102(12):1741-1748. PubMed ID: 37680134 [TBL] [Abstract][Full Text] [Related]
57. The feasibility of a randomized clinical perinatal trial: maternal magnesium sulfate for the prevention of cerebral palsy. Rouse DJ; Hauth JC; Nelson KG; Goldenberg RL Am J Obstet Gynecol; 1996 Sep; 175(3 Pt 1):701-5. PubMed ID: 8828437 [TBL] [Abstract][Full Text] [Related]
58. Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants. Bouet PE; Brun S; Madar H; Baisson AL; Courtay V; Gascoin-Lachambre G; Lasocki S; Sentilhes L Sci Rep; 2015 Sep; 5():14732. PubMed ID: 26415713 [TBL] [Abstract][Full Text] [Related]
59. Magnesium sulphate for the prevention of cerebral palsy in Australia and New Zealand. Bain E; Goodchild L; Lontis R; McIntyre S; Ashwood P; Bubner T; Middleton P; Crowther C Aust Nurs J; 2013 Jul; 21(1):34-7. PubMed ID: 23930314 [No Abstract] [Full Text] [Related]
60. Maternal adverse effects with different loading infusion rates of antenatal magnesium sulphate for preterm fetal neuroprotection: the IRIS randomised trial. Bain ES; Middleton PF; Yelland LN; Ashwood PJ; Crowther CA BJOG; 2014 Apr; 121(5):595-603. PubMed ID: 24387624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]